The Top 5 Analyst Questions From Moderna's Q1 Earnings Call
Moderna's first quarter results were met with a negative market reaction, as revenue fell short of Wall Street expectations and declined sharply versus the prior year. Management attributed the performance primarily to the seasonal nature of respiratory vaccine sales and lower overall COVID vaccination rates, which have become more routine rather than urgent. CEO Stephane Bancel pointed to progress in cost reduction efforts, highlighting a 19% reduction in combined cost of sales, research and development, and selling, general and administrative expenses as a sign of ongoing financial discipline.
Is now the time to buy MRNA? Find out in our full research report (it's free).
Revenue: $108 million vs analyst estimates of $117.9 million (35.3% year-on-year decline, 8.4% miss)
Adjusted EPS: -$2.52 vs analyst estimates of -$3.11 (18.9% beat)
The company reconfirmed its revenue guidance for the full year of $2 billion at the midpoint
Market Capitalization: $10.39 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Salveen Richter (Goldman Sachs) pressed for detail on the FDA's requirement for additional flu vaccine efficacy data and its impact on the timing for the flu/COVID combination, to which CEO Stephane Bancel explained the scientific rationale and anticipated review extension.
Jasmine (UBS, for Eliana Merle) sought clarity on whether Phase 3 data for individualized neoantigen therapy (INT) remains on track for 2026, and inquired about trial expansion plans. President Stephen Hoge reiterated timelines are event-driven but remain possible, with further updates pending.
Tyler Van Buren (TD Cowen) asked about the likelihood of approval for the next-generation COVID vaccine given recent regulatory leadership changes. Hoge responded that interactions with the FDA have been 'business as usual,' with no change in review process observed.
Courtney Breen (Bernstein) questioned the drivers and flexibility behind the expanded cost-cutting program. CFO Jamey Mock explained that cost reductions are largely tied to the winding down of large Phase 3 trials and ongoing process improvements, rather than specific revenue signals.
Gena Wang (Barclays) asked about U.S. COVID vaccine market share and future prospects, to which Mock replied that script data supports a stable market position and attributed lower reported revenue to customer inventory management rather than underlying loss of share.
Looking ahead, the StockStory team will closely monitor (1) regulatory decisions for Moderna's next-generation COVID, RSV, and flu vaccines, (2) the pace and impact of ongoing cost reduction efforts as major clinical trials wind down, and (3) progress in late-stage pipeline programs—especially new data readouts for oncology and non-respiratory vaccines. Execution on product launches and continued market expansion will be key indicators of strategic progress.
Moderna currently trades at $26.84, down from $28.58 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it's free).
Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
Fehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
9 minutes ago
- Bloomberg
Philadelphia Transit Braces for Sweeping Service Cuts
Philadelphia commuters are set to lose dozens of bus routes, rail stations and five rail lines starting August 24, after the city's transit agency SEPTA voted on Thursday to approve a 2026 budget that slashes services by 45%. The budget will also raise fares by 21.5% as officials continue to press the state for help addressing a $213 million operating deficit. Since the Covid pandemic, mass transit across the US — faced with a collective $6 billion shortfall — has been hurtling toward a ' death spiral,' in which sweeping cuts decimate ridership, leading to declining revenues and further service reductions. Few systems are under more financial pressure than SEPTA, whose officials warn that the repercussions 'will be almost impossible to reverse,' and are likely to affect people well beyond the city, Sri Taylor reports. Today on CityLab: Philadelphia Transit System Votes to Cut Service by 45%, Hike Fares
Hamilton Spectator
an hour ago
- Hamilton Spectator
Movie theatre ‘visionary': Cineplex CEO Ellis Jacob praised as he plans retirement
TORONTO - Movie theatre giant Cineplex Inc. says president and chief executive Ellis Jacob will retire at the end of next year, in what industry watchers say marks the end of an era for the company. Cineplex board chair Phyllis Yaffe praised Jacob for his work in building the company over the past four decades. The company said Jacob will continue to lead Cineplex in the interim and help in the transition to new leadership. 'Ellis is, quite simply, a giant in our industry,' Yaffe said in a press release. 'It has been a privilege to work alongside him for many years and we look forward to working with him through this transition.' Jacob was appointed president and chief executive of Cineplex in 2003 when the Canadian assets of Lowes Cineplex Entertainment and Galaxy Entertainment Inc. were merged. Before his current role, Jacob was president and CEO of Galaxy Entertainment, which he co-founded in 1999. That shift more than 20 years ago marked the first time in decades that Canada's movie theatre footprint was largely owned by Canadian companies, said Paul Moore, a professor of film history at Toronto Metropolitan University. 'Ellis Jacob is there at the helm of another moment of a big transition in the industry here in Canada — he's at the helm of actually creating a Canadian-owned business that runs the majority of movie theatres across Canada,' said Moore. 'Historically, if you look back from the 1930s all the way up to the 1990s, there's always been concern about our movie theatres are owned by Hollywood, and that's why we don't see our own stories on screen. Well, for 20 years now, we've had Cineplex being Canadian-owned.' Moore said the company has navigated a number of challenges during Jacob's leadership, including the rise of streaming platforms and plummeting box office sales during the COVID-19 pandemic. He said the company has pulled through 'partly because of its gorilla-sized proportion of the market' in Canada. 'So whenever a blockbuster does come along like Top Gun Maverick or most recently, the Minecraft movie, it's almost always a Cineplex theatre that Canadians go see that big blockbuster,' said Moore. 'And it's kind of protected them to a certain extent from competition domestically, and helped the transition here in Canada of the decline of everyday movie-going and the real shift to only occasional blockbuster movie-going.' Cineplex spent much of the pandemic period grappling with the fallout from its failed sale to U.K. theatre company Cineworld Group PLC. The scuttled $2.8 billion deal wound up in a court battle meant to decide whether Cineworld had the right to walk away from the transaction. A judge sided with Cineplex, but Cineworld made an appeal before it filed for bankruptcy in the United States. Cineplex has since said it does not expect to meaningfully recoup its costs. Today, Cineplex has more than 170 movie theatres and entertainment venues across Canada. The company has also long run its RecRoom arcade and dining venues, which Moore noted has helped diversify the movie-going experience for consumers. In a statement, Jacob said he has 'unwavering confidence in Cineplex's bright future' and was committed to working with the company's board as it transitions to a new CEO. 'After thoughtful consideration, I welcome this next chapter,' he said. 'For decades, I have been focused on making Cineplex a great Canadian company, and I move forward with immense pride in what we've built for generations of Canadian movie fans who come to us for those magical moments of escape that can only be found in a true theatre experience.' RBC analyst Drew McReynolds said Jacob 'has been the visionary beating heart of not only Cineplex but the broader theatrical exhibition industry for decades.' 'While these shoes are next to impossible to fill, we expect the leadership transition at Cineplex to be seamless and believe the transition timing is consistent with what should be a full industry recovery by 2026,' McReynolds said in a note on Friday. This report by The Canadian Press was first published June 27, 2025. Companies in this story: (TSX:CGX)
Business Wire
an hour ago
- Business Wire
SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta and certain of Sarepta's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Sarepta class action lawsuit, please provide your information here: CASE ALLEGATIONS: Sarepta is a commercial-stage biopharmaceutical company. According to the complaint, during the Class Period, Sarepta was engaged in the development of therapies to treat Duchenne muscular dystrophy ('Duchenne'), including ELEVIDYS (a prescription gene therapy intended for a limited category of people with Duchenne). The Sarepta Therapeutics class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; and (iii) the severity of adverse events from ELEVIDYS treatment would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals. The Sarepta class action lawsuit further alleges that on March 18, 2025, Sarepta revealed that a patient treated with ELEVIDYS suffered acute liver failure leading to death, which represented 'a severity of acute liver injury not previously reported for ELEVIDYS.' On this news, the price of Sarepta stock fell more than 27%, according to the complaint. Then, on April 4, 2025, the Sarepta class action lawsuit further alleges that Sarepta disclosed that European Union member country authorities had requested that the independent data monitoring committee meet to review the death announced on March 18, 2025, resulting in Sarepta halting recruitment and dosing in some of the ELEVIDYS clinical studies. On this news, the price of Sarepta stock fell more than 7%, according to the complaint. Thereafter, on June 15, 2025, Sarepta disclosed that a second patient had died of acute liver failure following treatment with ELEVIDYS, leading to Sarepta suspending shipment of ELEVIDYS for non-ambulatory patients and pausing dosing of ELEVIDYS in the ENVISION clinical study to evaluate the protocol in accordance with the U.S. Food and Drug Administration ('FDA'), according to the complaint. The Sarepta class action lawsuit alleges that on this news, the price of Sarepta stock fell more than 42%. Finally, the Sarepta class action lawsuit further alleges that on June 24, 2025, the FDA issued a Safety Communication announcing it had received reports of two deaths and was investigating the risk of acute liver failure with serious outcomes following treatment with ELEVIDYS. On this news, the price of Sarepta stock fell more than 8%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Sarepta securities during the Class Period to seek appointment as lead plaintiff in the Sarepta class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Sarepta class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Sarepta class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Sarepta class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
